Aequs Limited expanded its operational scope on August 07, 2026, when its Board of Directors approved alterations to Clause III(A) (Main Objects) of its Memorandum of Association. The changes are designed to align the company’s registered business activities with a proposed Scheme of Amalgamation involving three subsidiaries: Aerostructures Manufacturing India Private Limited, Aequs Engineered Plastics Private Limited, and Aequs Force Consumer Products Private Limited. This structural adjustment enables the company to formally engage in broader manufacturing sectors, including consumer products, precision engineering, and medical devices, following shareholder approval through a Postal Ballot process. The implementation remains subject to additional statutory and regulatory approvals.

The Board meeting commenced at 09:15 AM (IST) and concluded at 09:45 AM (IST) on August 07, 2026. In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company notified the National Stock Exchange of India Limited and BSE Limited. The disclosure also adhered to SEBI Circular No SEBI/HO/CFD/PoD2/I/3762/2026 dated January 30, 2026. Ravi Mallikarjun Hugar, Company Secretary and Compliance Officer, signed the intimation.

Expanded Business Objects

The alteration inserts Clauses 5 to 10 into the Main Objects section of the Memorandum of Association. These new clauses broaden the company’s permissible activities beyond its existing core operations. The specific additions include:

Strategic Implications

The inclusion of these clauses signals a strategic diversification into high-growth sectors such as consumer durables and medical devices. By formally registering these objects, Aequs Limited positions itself to leverage the capabilities of its subsidiaries post-amalgamation without requiring further charter amendments for each new product line. The approval by shareholders via Postal Ballot indicates strong internal support for this consolidation strategy. However, the finalization of the amalgamation depends on securing remaining statutory and regulatory clearances, which are not yet confirmed in the filing.

Aequs Limited has adopted a new equity incentive framework, approving the Aequs Restricted Stock Unit Plan 2026 (RSU 2026) and amending its existing Aequs Employee Stock Option Plan 2025 (ESOP 2025) during a Board meeting held on August 7, 2026. The move aims to broaden retention tools for employees across its global operations, including subsidiaries and associate companies in India and abroad. Simultaneously, the Nomination and Remuneration Committee granted 2,70,000 stock options under the ESOP 2025, signaling continued investment in human capital as part of its long-term growth strategy.

The Board’s decision, taken pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, involves reallocating resources from the existing ESOP pool. Specifically, 1,500,000 ungranted stock options from the ESOP 2025 pool have been earmarked for implementation of the RSU 2026. This reallocation results in a corresponding reduction in the ungranted options available for future grants under the ESOP 2025. Both the adoption of the RSU 2026 and the amendments to the ESOP 2025 are subject to shareholder approval at the company’s ensuing Annual General Meeting.

The amendment to the ESOP 2025 extends benefits to eligible employees of the company, its associate companies (including joint ventures), whether existing or future, located in India or outside India. This expansion aligns with the broader applicability of the new RSU 2026, which also covers employees of subsidiary companies. The structural changes ensure compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, providing a flexible mechanism for rewarding talent across the group’s diverse organizational structure.

In a separate disclosure under Regulation 30 read with Schedule III of the Listing Regulations and SEBI Circular No. HO/CFD/PoD2/I/3762/2026 dated January 30, 2026, the Nomination and Remuneration Committee approved the grant of 2,70,000 Employee Stock Options under the ESOP 2025 on August 7, 2026. These options carry an exercise price of ₹239.50 per option and represent shares with a face value of ₹10 each. The grant is subject to vesting conditions specified in the individual grant letters.

Key Terms of the ESOP Grant

The vested options will entitle holders to acquire an equal number of equity shares upon payment of the exercise price and applicable taxes. Once vested, the options must be exercised within three years. The total potential dilution from this specific grant amounts to 2,70,000 equity shares, assuming full vesting and exercise. The company has scheduled its 26th Annual General Meeting for September 4, 2026, to seek shareholder approval for these plans via Video Conferencing or Other Audio Visual Means.